255 related articles for article (PubMed ID: 28887325)
1. At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT.
Fitzhugh CD; Cordes S; Taylor T; Coles W; Roskom K; Link M; Hsieh MM; Tisdale JF
Blood; 2017 Oct; 130(17):1946-1948. PubMed ID: 28887325
[TBL] [Abstract][Full Text] [Related]
2. Effects of mixed hematopoietic chimerism in a mouse model of bone marrow transplantation for sickle cell anemia.
Iannone R; Luznik L; Engstrom LW; Tennessee SL; Askin FB; Casella JF; Kickler TS; Goodman SN; Hawkins AL; Griffin CA; Noffsinger L; Fuchs EJ
Blood; 2001 Jun; 97(12):3960-5. PubMed ID: 11389040
[TBL] [Abstract][Full Text] [Related]
3. Early Myeloid Derived Suppressor Cells (eMDSCs) Are Associated With High Donor Myeloid Chimerism Following Haploidentical HSCT for Sickle Cell Disease.
Bhat DK; Olkhanud PB; Gangaplara A; Seifuddin F; Pirooznia M; Biancotto A; Fantoni G; Pittman C; Francis B; Dagur PK; Saxena A; McCoy JP; Pfeiffer RM; Fitzhugh CD
Front Immunol; 2021; 12():757279. PubMed ID: 34917079
[TBL] [Abstract][Full Text] [Related]
4. Relationship between Mixed Donor-Recipient Chimerism and Disease Recurrence after Hematopoietic Cell Transplantation for Sickle Cell Disease.
Abraham A; Hsieh M; Eapen M; Fitzhugh C; Carreras J; Keesler D; Guilcher G; Kamani N; Walters MC; Boelens JJ; Tisdale J; Shenoy S; ;
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2178-2183. PubMed ID: 28882446
[TBL] [Abstract][Full Text] [Related]
5. Extensive multilineage analysis in patients with mixed chimerism after allogeneic transplantation for sickle cell disease: insight into hematopoiesis and engraftment thresholds for gene therapy.
Magnani A; Pondarré C; Bouazza N; Magalon J; Miccio A; Six E; Roudaut C; Arnaud C; Kamdem A; Touzot F; Gabrion A; Magrin E; Couzin C; Fusaro M; André I; Vernant JP; Gluckman E; Bernaudin F; Bories D; Cavazzana M
Haematologica; 2020 May; 105(5):1240-1247. PubMed ID: 31537695
[TBL] [Abstract][Full Text] [Related]
6. Evidence for ineffective erythropoiesis in severe sickle cell disease.
Wu CJ; Krishnamurti L; Kutok JL; Biernacki M; Rogers S; Zhang W; Antin JH; Ritz J
Blood; 2005 Nov; 106(10):3639-45. PubMed ID: 16091448
[TBL] [Abstract][Full Text] [Related]
7. In vivo measurement of RBC survival in patients with sickle cell disease before or after hematopoietic stem cell transplantation.
Leonard AK; Furstenau D; Inam Z; Luckett C; Chu R; Demirci S; Essawi K; Gudmundsdottir B; Hinds M; DiNicola J; Li Q; Eaton WA; Cellmer T; Wang X; Thein SL; Macari ER; VanNest S; Hsieh MM; Bonner M; Pierciey FJ; Tisdale JF
Blood Adv; 2024 Apr; 8(7):1806-1816. PubMed ID: 38181784
[TBL] [Abstract][Full Text] [Related]
8. Chimerism and cure: hematologic and pathologic correction of murine sickle cell disease.
Kean LS; Manci EA; Perry J; Balkan C; Coley S; Holtzclaw D; Adams AB; Larsen CP; Hsu LL; Archer DR
Blood; 2003 Dec; 102(13):4582-93. PubMed ID: 12933586
[TBL] [Abstract][Full Text] [Related]
9. Mixed donor chimerism following stem cell transplantation for sickle cell disease.
Shah NC; Rangarajan HG; Ngwube A; Shenoy S
Curr Opin Hematol; 2023 Nov; 30(6):187-193. PubMed ID: 37694765
[TBL] [Abstract][Full Text] [Related]
10. Molecular assessment of erythroid lineage chimerism following nonmyeloablative allogeneic stem cell transplantation.
Wu CJ; Hochberg EP; Rogers SA; Kutok JL; Biernacki M; Nascimento AF; Marks P; Bridges K; Ritz J
Exp Hematol; 2003 Oct; 31(10):924-33. PubMed ID: 14550808
[TBL] [Abstract][Full Text] [Related]
11. Curative therapies: Allogeneic hematopoietic cell transplantation from matched related donors using myeloablative, reduced intensity, and nonmyeloablative conditioning in sickle cell disease.
Guilcher GMT; Truong TH; Saraf SL; Joseph JJ; Rondelli D; Hsieh MM
Semin Hematol; 2018 Apr; 55(2):87-93. PubMed ID: 29958564
[TBL] [Abstract][Full Text] [Related]
12. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia.
Walters MC; Patience M; Leisenring W; Rogers ZR; Aquino VM; Buchanan GR; Roberts IA; Yeager AM; Hsu L; Adamkiewicz T; Kurtzberg J; Vichinsky E; Storer B; Storb R; Sullivan KM;
Biol Blood Marrow Transplant; 2001; 7(12):665-73. PubMed ID: 11787529
[TBL] [Abstract][Full Text] [Related]
13. Hematopoietic stem cell transplantation for sickle cell disease: state of the science.
Talano JA; Cairo MS
Eur J Haematol; 2015 May; 94(5):391-9. PubMed ID: 25200500
[TBL] [Abstract][Full Text] [Related]
14. Ex vivo immunological evaluation of stable mixed chimeric patients after matched related donor allogeneic transplantation in sickle cell disease.
Raines LN; Hsieh MM; Nassehi T; Drysdale CM; Tisdale JF; Uchida N
Cytotherapy; 2019 Dec; 21(12):1206-1215. PubMed ID: 31784240
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Effects of Allogeneic Hematopoietic Stem Cell Transplantation on Systemic Inflammation in Sickle Cell Disease Patients.
de Azevedo JTC; Costa TCM; Lima KC; Maciel TT; Palma PVB; Darrigo-Júnior LG; Setanni Grecco CE; Stracieri ABPL; Elias JB; Pieroni F; Guerino-Cunha RL; Pinto ACS; De Santis GC; Covas DT; Hermine O; Simões BP; Oliveira MC; Malmegrim KCR
Front Immunol; 2021; 12():774442. PubMed ID: 34956203
[TBL] [Abstract][Full Text] [Related]
16. Assessment of donor cell engraftment after hematopoietic stem cell transplantation for sickle cell disease: A review of current and future methods.
Lewis J; Greenway SC; Khan F; Singh G; Bhatia M; Guilcher GMT
Am J Hematol; 2022 Oct; 97(10):1359-1371. PubMed ID: 35583381
[TBL] [Abstract][Full Text] [Related]
17. Mixed chimerism following in utero hematopoietic stem cell transplantation in murine models of hemoglobinopathy.
Hayashi S; Abdulmalik O; Peranteau WH; Ashizuka S; Campagnoli C; Chen Q; Horiuchi K; Asakura T; Flake AW
Exp Hematol; 2003 Feb; 31(2):176-84. PubMed ID: 12591283
[TBL] [Abstract][Full Text] [Related]
18. Bone Marrow Transplantation after Nonmyeloablative Treosulfan Conditioning Is Curative in a Murine Model of Sickle Cell Disease.
Devadasan D; Sun CW; Westin ER; Wu LC; Pawlik KM; Townes TM; Goldman FD
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1554-1562. PubMed ID: 29684562
[TBL] [Abstract][Full Text] [Related]
19. Correction of murine hemoglobinopathies by prenatal tolerance induction and postnatal nonmyeloablative allogeneic BM transplants.
Peranteau WH; Hayashi S; Abdulmalik O; Chen Q; Merchant A; Asakura T; Flake AW
Blood; 2015 Sep; 126(10):1245-54. PubMed ID: 26124498
[TBL] [Abstract][Full Text] [Related]
20. Outpatient allografting in hematologic malignancies and nonmalignant disorders--applying lessons learned in the canine model to humans.
Maris M; Storb R
Cancer Treat Res; 2002; 110():149-75. PubMed ID: 11908197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
